1. Home
  2. VNRX

as 09-15-2025 2:34pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Nasdaq

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Founded: N/A Country:
United States
United States
Employees: N/A City: HENDERSON
Market Cap: 64.8M IPO Year: N/A
Target Price: $3.50 AVG Volume (30 days): 244.0K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.25 EPS Growth: N/A
52 Week Low/High: $0.40 - $0.94 Next Earning Date: 11-13-2025
Revenue: $1,319,252 Revenue Growth: 35.10%
Revenue Growth (this year): 274.46% Revenue Growth (next year): 212.60%

VNRX Daily Stock ML Predictions

Share on Social Networks: